Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

ABSTRACT:

Background

Aripiprazole has been reported to worsen psychotic symptoms when switching from other antipsychotics, possibly due to dopamine supersensitivity psychosis.

Objective

This study aimed to explore the predictors and possible underlying mechanisms of aripiprazole-related psychotic exacerbation.

Methods

We conducted an 8-week, open-label, randomized controlled study from October 2007 to September 2009, assigning patients with a primary diagnosis of schizophrenia or schizoaffective disorder to switch from other antipsychotics to aripiprazole with 2-week dual administration, and then to taper off the original agents in fast (n = 38, within 1 week) or slow (n = 41, within 4 weeks) strategies. Positive and Negative Syndrome Scale (PANSS) was examined at day 0, 7, 14,

SUBMITTER: Ma CH 

PROVIDER: S-EPMC8801645 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature